| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Graft vs Host Disease | 16 | 2014 | 2638 | 1.300 |
Why?
|
| Skin Diseases | 7 | 2018 | 349 | 0.960 |
Why?
|
| Granuloma | 3 | 2014 | 154 | 0.910 |
Why?
|
| Exanthema | 2 | 2019 | 211 | 0.860 |
Why?
|
| Lepidoptera | 1 | 2019 | 8 | 0.730 |
Why?
|
| Urticaria | 1 | 2019 | 23 | 0.710 |
Why?
|
| Skin Neoplasms | 10 | 2016 | 4654 | 0.610 |
Why?
|
| Dermatitis | 2 | 2014 | 60 | 0.560 |
Why?
|
| Psoriasis | 4 | 2019 | 126 | 0.500 |
Why?
|
| Herpes Zoster | 2 | 2014 | 50 | 0.490 |
Why?
|
| Skin Ulcer | 2 | 2014 | 77 | 0.490 |
Why?
|
| Herpesvirus 3, Human | 1 | 2014 | 43 | 0.470 |
Why?
|
| Plasmacytoma | 1 | 2014 | 111 | 0.460 |
Why?
|
| Scleroderma, Localized | 2 | 2012 | 12 | 0.460 |
Why?
|
| Skin | 10 | 2020 | 1259 | 0.460 |
Why?
|
| Drug Eruptions | 4 | 2018 | 256 | 0.440 |
Why?
|
| Hyperostosis | 1 | 2012 | 8 | 0.430 |
Why?
|
| Osteitis | 1 | 2012 | 17 | 0.430 |
Why?
|
| Synovitis | 1 | 2012 | 23 | 0.430 |
Why?
|
| Hand Dermatoses | 1 | 2012 | 25 | 0.430 |
Why?
|
| Acne Vulgaris | 1 | 2012 | 47 | 0.420 |
Why?
|
| Skin Diseases, Vesiculobullous | 3 | 2007 | 25 | 0.400 |
Why?
|
| Eccrine Porocarcinoma | 1 | 2011 | 2 | 0.400 |
Why?
|
| Spinal Diseases | 1 | 2012 | 125 | 0.390 |
Why?
|
| Pain | 1 | 2019 | 1658 | 0.390 |
Why?
|
| Facial Neoplasms | 1 | 2011 | 84 | 0.390 |
Why?
|
| Jewelry | 1 | 2010 | 2 | 0.390 |
Why?
|
| Candidiasis, Cutaneous | 1 | 2010 | 4 | 0.390 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2014 | 551 | 0.370 |
Why?
|
| Fusarium | 1 | 2010 | 50 | 0.370 |
Why?
|
| Dermatomycoses | 1 | 2010 | 42 | 0.370 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2011 | 71 | 0.370 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 9 | 2019 | 6550 | 0.350 |
Why?
|
| Pigmentation Disorders | 1 | 2009 | 38 | 0.350 |
Why?
|
| Folliculitis | 1 | 2009 | 7 | 0.350 |
Why?
|
| Mucinosis, Follicular | 1 | 2009 | 9 | 0.350 |
Why?
|
| Scleromyxedema | 1 | 2009 | 6 | 0.350 |
Why?
|
| Nail Diseases | 1 | 2009 | 40 | 0.350 |
Why?
|
| Candida | 1 | 2010 | 164 | 0.340 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2012 | 294 | 0.340 |
Why?
|
| Siphonaptera | 1 | 2008 | 8 | 0.340 |
Why?
|
| Toes | 1 | 2008 | 46 | 0.330 |
Why?
|
| Insect Bites and Stings | 1 | 2008 | 43 | 0.320 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2007 | 43 | 0.310 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 89 | 0.300 |
Why?
|
| Radiodermatitis | 1 | 2006 | 75 | 0.270 |
Why?
|
| Fluorouracil | 2 | 2009 | 1944 | 0.260 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 1 | 2009 | 426 | 0.260 |
Why?
|
| Biopsy | 9 | 2016 | 3443 | 0.250 |
Why?
|
| Bone Marrow Transplantation | 5 | 2014 | 1581 | 0.240 |
Why?
|
| Deoxycytidine | 1 | 2009 | 1353 | 0.240 |
Why?
|
| Gastrointestinal Agents | 1 | 2004 | 108 | 0.230 |
Why?
|
| Chronic Disease | 9 | 2014 | 1819 | 0.230 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2009 | 1299 | 0.230 |
Why?
|
| Hodgkin Disease | 1 | 2012 | 1429 | 0.230 |
Why?
|
| Oximes | 2 | 2016 | 175 | 0.230 |
Why?
|
| Papillomavirus Infections | 2 | 2013 | 980 | 0.220 |
Why?
|
| Lymphoma, Follicular | 1 | 2008 | 587 | 0.220 |
Why?
|
| Humans | 58 | 2020 | 261506 | 0.210 |
Why?
|
| Diagnosis, Differential | 6 | 2020 | 4744 | 0.210 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2012 | 1664 | 0.200 |
Why?
|
| Facial Dermatoses | 3 | 2005 | 26 | 0.200 |
Why?
|
| Langerhans Cell Sarcoma | 1 | 2020 | 15 | 0.190 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2016 | 1283 | 0.180 |
Why?
|
| Myelodysplastic Syndromes | 3 | 2008 | 2979 | 0.180 |
Why?
|
| Male | 32 | 2020 | 123000 | 0.180 |
Why?
|
| Lichenoid Eruptions | 2 | 2017 | 36 | 0.180 |
Why?
|
| PUVA Therapy | 2 | 2012 | 34 | 0.170 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2011 | 2390 | 0.170 |
Why?
|
| Merkel cell polyomavirus | 2 | 2016 | 30 | 0.170 |
Why?
|
| Imidazoles | 2 | 2016 | 999 | 0.170 |
Why?
|
| Middle Aged | 24 | 2020 | 86204 | 0.170 |
Why?
|
| Organic Chemicals | 1 | 2018 | 113 | 0.160 |
Why?
|
| Amifostine | 2 | 2011 | 97 | 0.160 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 4367 | 0.160 |
Why?
|
| Radiation-Protective Agents | 2 | 2011 | 128 | 0.160 |
Why?
|
| Melanoma | 5 | 2020 | 5317 | 0.150 |
Why?
|
| Immunocompromised Host | 2 | 2014 | 698 | 0.150 |
Why?
|
| Aged | 20 | 2020 | 70117 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2016 | 5437 | 0.150 |
Why?
|
| Acute Disease | 2 | 2012 | 2422 | 0.140 |
Why?
|
| Hydroxychloroquine | 2 | 1996 | 32 | 0.140 |
Why?
|
| RNA, Small Cytoplasmic | 2 | 1986 | 8 | 0.140 |
Why?
|
| Warts | 1 | 2016 | 19 | 0.140 |
Why?
|
| Melanocytes | 2 | 2015 | 219 | 0.140 |
Why?
|
| Antineoplastic Agents | 7 | 2018 | 14289 | 0.140 |
Why?
|
| Wilms Tumor | 1 | 2018 | 292 | 0.130 |
Why?
|
| Ribonucleoproteins | 2 | 1986 | 123 | 0.130 |
Why?
|
| Interferon-alpha | 2 | 2017 | 889 | 0.130 |
Why?
|
| Graft vs Host Reaction | 2 | 1985 | 59 | 0.130 |
Why?
|
| Calcinosis | 1 | 2018 | 423 | 0.130 |
Why?
|
| Angiomatosis | 1 | 2014 | 26 | 0.120 |
Why?
|
| Female | 31 | 2020 | 141928 | 0.120 |
Why?
|
| Hepacivirus | 1 | 2017 | 397 | 0.120 |
Why?
|
| Alopecia Areata | 2 | 2014 | 55 | 0.120 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 3022 | 0.120 |
Why?
|
| Skin Transplantation | 1 | 1994 | 173 | 0.120 |
Why?
|
| Cyclin D1 | 1 | 2015 | 576 | 0.110 |
Why?
|
| Pemphigus | 1 | 1992 | 8 | 0.110 |
Why?
|
| Lupus Erythematosus, Discoid | 2 | 1989 | 4 | 0.110 |
Why?
|
| Papillomaviridae | 1 | 2016 | 624 | 0.110 |
Why?
|
| Ultraviolet Therapy | 1 | 2012 | 10 | 0.110 |
Why?
|
| Stem Cell Transplantation | 2 | 2011 | 1360 | 0.110 |
Why?
|
| Syphilis, Cutaneous | 1 | 1992 | 8 | 0.110 |
Why?
|
| Phototherapy | 1 | 2012 | 75 | 0.100 |
Why?
|
| Administration, Topical | 1 | 2012 | 257 | 0.100 |
Why?
|
| Gadolinium DTPA | 1 | 2012 | 172 | 0.100 |
Why?
|
| Tumor Virus Infections | 1 | 2013 | 224 | 0.100 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2013 | 155 | 0.100 |
Why?
|
| Immunohistochemistry | 5 | 2020 | 7548 | 0.100 |
Why?
|
| Biopsy, Needle | 3 | 2014 | 1363 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2012 | 1833 | 0.090 |
Why?
|
| Pericarditis | 1 | 2011 | 61 | 0.090 |
Why?
|
| Itraconazole | 1 | 2010 | 77 | 0.090 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2016 | 4757 | 0.090 |
Why?
|
| Adult | 22 | 2020 | 77950 | 0.090 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2011 | 74 | 0.090 |
Why?
|
| Dermatologic Agents | 1 | 2010 | 53 | 0.090 |
Why?
|
| Diphosphonates | 1 | 2012 | 262 | 0.090 |
Why?
|
| Voriconazole | 1 | 2010 | 108 | 0.090 |
Why?
|
| Hematologic Neoplasms | 2 | 2019 | 1870 | 0.090 |
Why?
|
| Child, Preschool | 5 | 2020 | 16273 | 0.090 |
Why?
|
| Syndrome | 1 | 2012 | 1351 | 0.080 |
Why?
|
| Hyperpigmentation | 1 | 2008 | 32 | 0.080 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2011 | 199 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2012 | 461 | 0.080 |
Why?
|
| Adenine Nucleotides | 1 | 2010 | 351 | 0.080 |
Why?
|
| Combined Modality Therapy | 2 | 2012 | 8865 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2012 | 544 | 0.080 |
Why?
|
| Capecitabine | 1 | 2009 | 388 | 0.080 |
Why?
|
| Brachytherapy | 2 | 2012 | 977 | 0.080 |
Why?
|
| Epidermodysplasia Verruciformis | 1 | 2007 | 20 | 0.080 |
Why?
|
| Autoantigens | 2 | 1986 | 234 | 0.080 |
Why?
|
| Arabinonucleosides | 1 | 2010 | 437 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2009 | 272 | 0.080 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 1350 | 0.070 |
Why?
|
| Lupus Erythematosus, Systemic | 2 | 1986 | 223 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 1 | 2012 | 585 | 0.070 |
Why?
|
| Ancillary Services, Hospital | 1 | 2006 | 2 | 0.070 |
Why?
|
| Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2006 | 19 | 0.070 |
Why?
|
| Carcinoma, Medullary | 1 | 2008 | 248 | 0.070 |
Why?
|
| Photosensitivity Disorders | 1 | 1986 | 23 | 0.070 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 1294 | 0.070 |
Why?
|
| Antibodies, Antinuclear | 1 | 1986 | 46 | 0.070 |
Why?
|
| Drainage | 1 | 2008 | 416 | 0.070 |
Why?
|
| Triazoles | 1 | 2010 | 617 | 0.070 |
Why?
|
| Scleroderma, Systemic | 2 | 1990 | 134 | 0.070 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 3719 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 3251 | 0.070 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2005 | 5 | 0.070 |
Why?
|
| Contrast Media | 1 | 2012 | 1472 | 0.070 |
Why?
|
| Photopheresis | 1 | 2005 | 79 | 0.070 |
Why?
|
| Low-Level Light Therapy | 1 | 2005 | 24 | 0.060 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2011 | 713 | 0.060 |
Why?
|
| Antigens | 1 | 1986 | 292 | 0.060 |
Why?
|
| Lichen Planus | 1 | 1985 | 22 | 0.060 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 2326 | 0.060 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2004 | 42 | 0.060 |
Why?
|
| Photochemotherapy | 1 | 1985 | 96 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 1375 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 12926 | 0.060 |
Why?
|
| Cytarabine | 1 | 2010 | 1973 | 0.060 |
Why?
|
| Infliximab | 1 | 2004 | 130 | 0.060 |
Why?
|
| Infection Control | 1 | 2006 | 270 | 0.060 |
Why?
|
| Radiation Injuries | 1 | 2011 | 1411 | 0.060 |
Why?
|
| Treatment Outcome | 6 | 2020 | 32848 | 0.050 |
Why?
|
| Sirolimus | 1 | 2006 | 814 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2004 | 268 | 0.050 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 748 | 0.050 |
Why?
|
| Animals | 3 | 2019 | 59536 | 0.050 |
Why?
|
| Busulfan | 1 | 1985 | 764 | 0.050 |
Why?
|
| Panniculitis, Lupus Erythematosus | 2 | 1991 | 3 | 0.050 |
Why?
|
| Lymphoma, B-Cell | 1 | 2007 | 895 | 0.050 |
Why?
|
| Algorithms | 1 | 2012 | 3890 | 0.050 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2010 | 6915 | 0.050 |
Why?
|
| S100 Proteins | 1 | 2020 | 181 | 0.050 |
Why?
|
| Carcinoma | 1 | 2011 | 2578 | 0.040 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 14889 | 0.040 |
Why?
|
| Anemia, Aplastic | 2 | 2005 | 214 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 1994 | 5542 | 0.040 |
Why?
|
| Mutation | 2 | 2016 | 15179 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 259 | 0.040 |
Why?
|
| Adolescent | 9 | 2020 | 31252 | 0.040 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2018 | 153 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2010 | 3518 | 0.040 |
Why?
|
| Thyroid Neoplasms | 1 | 2008 | 1866 | 0.040 |
Why?
|
| Multiple Myeloma | 1 | 2008 | 2138 | 0.040 |
Why?
|
| Allografts | 1 | 2019 | 650 | 0.040 |
Why?
|
| Minoxidil | 1 | 1996 | 8 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2019 | 12873 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2012 | 7551 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2008 | 2992 | 0.030 |
Why?
|
| Alopecia | 1 | 1996 | 126 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 7702 | 0.030 |
Why?
|
| Young Adult | 3 | 2020 | 21445 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2018 | 604 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 29902 | 0.030 |
Why?
|
| Acyclovir | 1 | 1994 | 78 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 1996 | 167 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2017 | 2927 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2011 | 1234 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7789 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2014 | 495 | 0.030 |
Why?
|
| Azathioprine | 1 | 1992 | 66 | 0.030 |
Why?
|
| Infant | 3 | 2020 | 13310 | 0.030 |
Why?
|
| Sunlight | 1 | 1992 | 79 | 0.030 |
Why?
|
| Age Distribution | 1 | 2014 | 698 | 0.030 |
Why?
|
| Siblings | 1 | 2014 | 285 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2016 | 710 | 0.030 |
Why?
|
| Recurrence | 1 | 2020 | 4758 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 2013 | 139 | 0.030 |
Why?
|
| Carcinoma, Basal Cell | 1 | 1994 | 272 | 0.030 |
Why?
|
| Exophthalmos | 1 | 1991 | 45 | 0.020 |
Why?
|
| Retrospective Studies | 4 | 2016 | 37905 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2013 | 694 | 0.020 |
Why?
|
| Elastic Tissue | 1 | 1990 | 34 | 0.020 |
Why?
|
| Orbital Diseases | 1 | 1991 | 118 | 0.020 |
Why?
|
| Incidence | 2 | 2014 | 5673 | 0.020 |
Why?
|
| Prednisone | 1 | 1992 | 984 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 4320 | 0.020 |
Why?
|
| Child | 4 | 2020 | 29154 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2020 | 15862 | 0.020 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2012 | 10035 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2014 | 769 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 2450 | 0.020 |
Why?
|
| Edema | 1 | 1991 | 267 | 0.020 |
Why?
|
| Risk Factors | 1 | 2006 | 17523 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 1996 | 3890 | 0.020 |
Why?
|
| Laryngeal Neoplasms | 1 | 1992 | 518 | 0.020 |
Why?
|
| Comorbidity | 1 | 2014 | 2352 | 0.020 |
Why?
|
| Prognosis | 3 | 2014 | 21713 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2014 | 6869 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 2218 | 0.020 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 10001 | 0.020 |
Why?
|
| Living Donors | 1 | 2007 | 171 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 3203 | 0.020 |
Why?
|
| Bortezomib | 1 | 2008 | 543 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2008 | 362 | 0.020 |
Why?
|
| Complement C2 | 1 | 1986 | 2 | 0.020 |
Why?
|
| Antigen-Antibody Complex | 1 | 1986 | 115 | 0.020 |
Why?
|
| Pyrazines | 1 | 2008 | 495 | 0.020 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2006 | 208 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 216 | 0.020 |
Why?
|
| Lymphatic Metastasis | 2 | 2011 | 4844 | 0.020 |
Why?
|
| Erythema Multiforme | 1 | 2004 | 14 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 2238 | 0.020 |
Why?
|
| Pathology | 1 | 2006 | 101 | 0.020 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2004 | 21 | 0.020 |
Why?
|
| Blister | 1 | 2004 | 31 | 0.020 |
Why?
|
| Sjogren's Syndrome | 1 | 1986 | 102 | 0.020 |
Why?
|
| Logistic Models | 1 | 2012 | 3441 | 0.020 |
Why?
|
| Leukemia, Lymphoid | 1 | 1985 | 276 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 1985 | 307 | 0.020 |
Why?
|
| Drug Resistance | 1 | 2005 | 587 | 0.020 |
Why?
|
| Cyclophosphamide | 2 | 1996 | 3001 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 2432 | 0.020 |
Why?
|
| Steroids | 1 | 2005 | 356 | 0.010 |
Why?
|
| Eye | 1 | 2005 | 301 | 0.010 |
Why?
|
| Everolimus | 1 | 2006 | 415 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 1986 | 575 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2008 | 1450 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 366 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 4988 | 0.010 |
Why?
|
| HLA Antigens | 1 | 1986 | 546 | 0.010 |
Why?
|
| Infant, Newborn | 2 | 1986 | 8223 | 0.010 |
Why?
|
| Chemoradiotherapy | 1 | 2012 | 1946 | 0.010 |
Why?
|
| Remission Induction | 1 | 2008 | 3569 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 339 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2014 | 9244 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 846 | 0.010 |
Why?
|
| Age Factors | 2 | 1990 | 5377 | 0.010 |
Why?
|
| Disease Management | 1 | 2006 | 1052 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 1985 | 1620 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 2005 | 2843 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2005 | 2315 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 1989 | 2967 | 0.010 |
Why?
|
| DNA | 1 | 1986 | 2693 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 15694 | 0.010 |
Why?
|
| Hair | 1 | 1996 | 42 | 0.010 |
Why?
|
| Administration, Cutaneous | 1 | 1996 | 141 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 2961 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 2403 | 0.010 |
Why?
|
| Placebos | 1 | 1996 | 437 | 0.010 |
Why?
|
| CD4-CD8 Ratio | 1 | 1993 | 58 | 0.010 |
Why?
|
| Drug Tolerance | 1 | 1993 | 114 | 0.010 |
Why?
|
| Lymphocyte Subsets | 1 | 1993 | 137 | 0.010 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 1996 | 588 | 0.010 |
Why?
|
| Methotrexate | 1 | 1996 | 999 | 0.010 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1996 | 726 | 0.010 |
Why?
|
| Pregnancy | 1 | 1986 | 7573 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1993 | 266 | 0.010 |
Why?
|
| Arthritis, Rheumatoid | 1 | 1996 | 410 | 0.010 |
Why?
|
| Eyelid Diseases | 1 | 1991 | 76 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 1996 | 2588 | 0.010 |
Why?
|
| Back | 1 | 1990 | 45 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1996 | 2803 | 0.010 |
Why?
|
| Atrophy | 1 | 1990 | 261 | 0.010 |
Why?
|
| Necrosis | 1 | 1991 | 580 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1993 | 1544 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1996 | 3005 | 0.010 |
Why?
|
| United States | 1 | 2006 | 15433 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1989 | 660 | 0.010 |
Why?
|
| Neoplasms | 1 | 1993 | 15193 | 0.000 |
Why?
|
| Mice | 1 | 1986 | 34495 | 0.000 |
Why?
|
| Lymph Node Excision | 1 | 1989 | 1959 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1993 | 3341 | 0.000 |
Why?
|